Dr. Premal Lulla, MD
Claim this profileHouston Methodist Hospital
Studies Multiple Myeloma
Studies Acute Myelogenous Leukemia
8 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials Premal Lulla, MD is currently running
CAR-T Cell Therapy
for Lymphoma
This study involves patients that have a cancer called diffuse large B cell lymphoma (DLBCL), Natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma). Patients' lymphoma has come back or not gone away after treatment. A previous research study at Baylor combined two ways of fighting disease: antibodies and T cells. Antibodies are proteins that bind to bacteria, viruses and other foreign substances to prevent disease. T-cells are special infection-fighting white blood cells that can kill tumor cells or cells infected with bacteria and viruses. Both have shown promise treating cancer, but neither has been strong enough to cure most patients. In the previous study, an antibody called anti-CD30 which is found on the surface of some T-cells and cancer cells, and had been used to treat lymphoma with limited success, was joined to the T-cells through a process called gene transfer, resulting in CD30.CAR T cells. Another study saw encouraging responses using CD30.CAR T cells made in a lab from a patients' own blood then injected back into the same patient to treat their lymphoma. These cells are termed 'autologous' because they're given back to the original patient. In an ongoing study, patients were treated with allogeneic CD30.CAR T cells, which are made from healthy donors instead of the patients. The use of allogenic cells avoids a lengthy manufacture time since the products are stored as a bank and available on demand. This ongoing trial has preliminarily shown promising clinical activity with no safety concerns. With the current study, investigators plan to extend the anti-cancer effects of the CD30.CAR T cell by attaching another molecule called C7R, which has made CAR T cells have deeper and longer anticancer effects in the laboratory. The aim is to study the safety and effectiveness of allogeneic banked CD30.CAR-EBVST cells that also carry the C7R molecule, to learn the side effects of C7R modified CD30.CAR-EBVST cells in lymphoma patients, and to see whether this therapy may help them. As an extra safety step, the C7R containing T cells will also have a marker called iC9. If a patient experiences intolerable side effects from the C7R T cells, they could receive a medication called 'rimiducid' that can eliminate the C7R containing T cells by binding iC9, thereby potentially resolving the side effects. While not yet FDA approved, rimiducid has been tested in patients before without bad side effects.
Recruiting1 award Phase 1
TAA-Specific Cytotoxic T-Lymphocytes
for Multiple Myeloma
This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). MGUS and SM have tumor cells that possess nearly identical properties to the cancer cells seen in patients with multiple myeloma. The investigators would like to target proteins that are expressed by these cells using the patient's own immune cells known as T lymphocytes.This research study uses special immune system cells called tumor associated antigen (TAA)-specific cytotoxic T lymphocytes (CTLs), a new experimental therapy. The proteins that investigators are targeting in this study are called tumor associated antigens (TAAs). These are cell proteins that are specific to the cancer cell.They either do not show or show up in low quantities on normal human cells. In this study the investigators are targeting five common TAAs called NY-ESO-1, MAGEA4, PRAME, Survivin and SSX. On a different protocol, patients have been treated and so far this treatment has shown to be safe. Investigators now want to try this treatment in patients with multiple myeloma or if the investigators can arrest the progression of the patient's condition condition (described above) to multiple myeloma. These TAA-specific CTLs are an investigational product not approved by the Food and Drug Administration. The purpose of this study is to find the largest safe dose of TAA-specific CTLs, to learn what the side effects are, and to see whether this therapy might help patients with multiple myeloma monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM) .
Recruiting1 award Phase 116 criteria
More about Premal Lulla, MD
Clinical Trial Related1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Premal Lulla, MD has experience with
- TAA-specific CTLs
- CVD908ssb-TXSVN
- MultiTAA-specific T Cells
- C7R.CD30.CAR-EBVST Cells
- Partially HLA-matched SARS-CoVSTs
- STRIDE Biorepository
Breakdown of trials Premal Lulla, MD has run
Multiple Myeloma
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Hematologic Malignancies
Myelodysplastic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Premal Lulla, MD specialize in?
Premal Lulla, MD focuses on Multiple Myeloma and Acute Myelogenous Leukemia. In particular, much of their work with Multiple Myeloma has involved treating patients, or patients who are undergoing treatment.
Is Premal Lulla, MD currently recruiting for clinical trials?
Yes, Premal Lulla, MD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Premal Lulla, MD has studied deeply?
Yes, Premal Lulla, MD has studied treatments such as TAA-specific CTLs, CVD908ssb-TXSVN, MultiTAA-specific T cells.
What is the best way to schedule an appointment with Premal Lulla, MD?
Apply for one of the trials that Premal Lulla, MD is conducting.
What is the office address of Premal Lulla, MD?
The office of Premal Lulla, MD is located at: Houston Methodist Hospital, Houston, Texas 77030 United States. This is the address for their practice at the Houston Methodist Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.